# Current progresses
Time-stamp: <2017-10-23 10:15:38>

## Clinic practice 
1. (Mon Oct 23 10:09:39 PDT 2017) [Rare Tumor Clinic @UCSD](https://health.ucsd.edu/specialties/cancer/programs/personalized-therapy/Pages/rare-tumor.aspx): 
   * ( Oct 16 2017): [Kato et al. 2017 The Oncologist](http://theoncologist.alphamedpress.org/content/early/2017/10/15/theoncologist.2017-0199.full.pdf+html): Matched theraphy n significantly longer progressionfree survival compared with last prior unmatched therapy. [HR](https://en.wikipedia.org/wiki/Hazard_ratio)=.26; 60% 20 month vs. <5 month.  

## Cancer gene therapy 

1. (2017-08-30) Novartis' Kymriah [FDA](https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm):
   * Target: ALL (acute lymphoblastic leukemia) for certain pediatric and young adult patients 
   * [press](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm)
   * Scientific reference: [Porter et al. 2015, Sci Transl Med](https://www.ncbi.nlm.nih.gov/pubmed/26333935)
   
2. (2017-10-18) Yescarta from Kite [FDA product](https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm)
   * [NYCtimes](https://www.nytimes.com/2017/10/18/health/immunotherapy-cancer-kite.html?_r=0)
   * [Notice from FDA](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm)
     *  [Priority Review](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm), [Breakthrough Therapy](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405399.htm), [Orphan Drug](https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/TipsforApplyingforOrphanProductDesignation/default.htm)
   * Target: CRS (cytokine release syndrome) 
     * CAR (chimeric antigen receptor) T cell therpy | 1st for certain types of NHL (non-Hodgkin lymphoma) 
   * Scientific reference: [Lee et al. Blodd 2014](https://www.ncbi.nlm.nih.gov/pubmed/24876563)

## References

* [what is gene therapy?(FDA)](https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm573960.htm)
* [FDA: CEBR (center for biologics Evaluation and Research)](https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm)






